1-19 of 19
Yu-Tzu Tai
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma

Keiji Kurata, Mehmet K. Samur, Priscilla Liow, Kenneth Wen, Leona Yamamoto, Jiye Liu, Eugenio Morelli, Annamaria Gulla, Yu-Tzu Tai, Jun Qi, Teru Hideshima, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3956.
https://doi.org/10.1158/1078-0432.CCR-24-2112
Published: 03 September 2024
View article titled, Correction: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Open the PDF for Correction: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma in another window
Journal Articles

BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma

Keiji Kurata, Mehmet K. Samur, Priscilla Liow, Kenneth Wen, Leona Yamamoto, Jiye Liu, Eugenio Morelli, Annamaria Gulla, Yu-Tzu Tai, Jun Qi, Teru Hideshima, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (9): 1807–1821.
https://doi.org/10.1158/1078-0432.CCR-22-3668
Published: 01 May 2023
View article titled, BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Open the PDF for BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Microenvironment Is a Key Determinant of Immune Checkpoint Inhibitor Response

Shih-Feng Cho, Kenneth C. Anderson, Yu-Tzu Tai
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1479–1481.
https://doi.org/10.1158/1078-0432.CCR-22-0015
Published: 14 April 2022
View article titled, Microenvironment Is a Key Determinant of Immune Checkpoint Inhibitor Response
Open the PDF for Microenvironment Is a Key Determinant of Immune Checkpoint Inhibitor Response in another window
Journal Articles

BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression

Lijie Xing, Su Wang, Jiye Liu, Tengteng Yu, Hailin Chen, Kenneth Wen, Yuyin Li, Liang Lin, Phillip A. Hsieh, Shih-Feng Cho, Gang An, Lugui Qiu, Krista Kinneer, Nikhil Munshi, Kenneth C. Anderson, Yu-Tzu Tai
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5376–5388.
https://doi.org/10.1158/1078-0432.CCR-21-1621
Published: 01 October 2021
View article titled, BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression
Open the PDF for BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression in another window
Includes: Supplementary data
Journal Articles

Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

Claire Fabre, Naoya Mimura, Kathryn Bobb, Sun-Young Kong, Güllü Gorgun, Diana Cirstea, Yiguo Hu, Jiro Minami, Hiroto Ohguchi, Jie Zhang, Jeffrey Meshulam, Ruben D. Carrasco, Yu-Tzu Tai, Paul G. Richardson, Teru Hideshima, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (9): 2938.
https://doi.org/10.1158/1078-0432.CCR-19-0959
Published: 01 May 2019
View article titled, Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
Open the PDF for Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma in another window
Journal Articles

SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads

Krista Kinneer, John Meekin, Arnaud C. Tiberghien, Yu-Tzu Tai, Sandrina Phipps, Christine Mione Kiefer, Marlon C. Rebelatto, Nazzareno Dimasi, Alyssa Moriarty, Kyriakos P. Papadopoulos, Sriram Sridhar, Stephen J. Gregson, Michael J. Wick, Luke Masterson, Kenneth C. Anderson, Ronald Herbst, Philip W. Howard, David A. Tice
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6570–6582.
https://doi.org/10.1158/1078-0432.CCR-18-1300
Published: 13 December 2018
View article titled, SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads
Open the PDF for SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads in another window
Includes: Supplementary data
Journal Articles

Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma

Morihiko Sagawa, Hiroto Ohguchi, Takeshi Harada, Mehmet K. Samur, Yu-Tzu Tai, Nikhil C. Munshi, Masahiro Kizaki, Teru Hideshima, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 5225–5237.
https://doi.org/10.1158/1078-0432.CCR-17-0263
Published: 31 August 2017
View article titled, Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma
Open the PDF for Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma

Xiaoyan Feng, Li Zhang, Chirag Acharya, Gang An, Kenneth Wen, Lugui Qiu, Nikhil C. Munshi, Yu-Tzu Tai, Kenneth C. Anderson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (15): 4290–4300.
https://doi.org/10.1158/1078-0432.CCR-16-3192
Published: 01 August 2017
View article titled, Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma
Open the PDF for Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status

Michele Cea, Antonia Cagnetta, Chirag Acharya, Prakrati Acharya, Yu-Tzu Tai, Cao Yang, Davide Lovera, Debora Soncini, Maurizio Miglino, Giulio Fraternali-Orcioni, Luca Mastracci, Alessio Nencioni, Fabrizio Montecucco, Fiammetta Monacelli, Alberto Ballestrero, Teru Hideshima, Dharminder Chauhan, Marco Gobbi, Roberto M. Lemoli, Nikhil Munshi, Steven P. Treon, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (24): 6099–6109.
https://doi.org/10.1158/1078-0432.CCR-16-0630
Published: 15 December 2016
View article titled, Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status
Open the PDF for Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status in another window
Includes: Supplementary data
Journal Articles

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

Güllü Görgün, Mehmet K. Samur, Kristen B. Cowens, Steven Paula, Giada Bianchi, Julie E. Anderson, Randie E. White, Ahaana Singh, Hiroto Ohguchi, Rikio Suzuki, Shohei Kikuchi, Takeshi Harada, Teru Hideshima, Yu-Tzu Tai, Jacob P. Laubach, Noopur Raje, Florence Magrangeas, Stephane Minvielle, Herve Avet-Loiseau, Nikhil C. Munshi, David M. Dorfman, Paul G. Richardson, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (20): 4607–4618.
https://doi.org/10.1158/1078-0432.CCR-15-0200
Published: 14 October 2015
View article titled, Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
Open the PDF for Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence In Situ Hybridization in Multiple Myeloma

Gang An, Zengjun Li, Yu-Tzu Tai, Chirag Acharya, Qian Li, Xiaoqi Qin, Shuhua Yi, Yan Xu, Xiaoyan Feng, Chengwen Li, Jiawei Zhao, Lihui Shi, Meirong Zang, Shuhui Deng, Weiwei Sui, Mu Hao, Dehui Zou, Yaozhong Zhao, Junyuan Qi, Tao Cheng, Kun Ru, Jianxiang Wang, Kenneth C Anderson, Lugui Qiu
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (9): 2148–2156.
https://doi.org/10.1158/1078-0432.CCR-14-2576
Published: 30 April 2015
View article titled, The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence <em>In Situ</em> Hybridization in Multiple Myeloma
Open the PDF for The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence <em>In Situ</em> Hybridization in Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma

Claire Fabre, Naoya Mimura, Kathryn Bobb, Sun-Young Kong, Güllü Gorgun, Diana Cirstea, Yiguo Hu, Jiro Minami, Hiroto Ohguchi, Jie Zhang, Jeffrey Meshulam, Ruben D. Carrasco, Yu-Tzu Tai, Paul G. Richardson, Teru Hideshima, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4669–4681.
https://doi.org/10.1158/1078-0432.CCR-12-0779
Published: 30 August 2012
View article titled, Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
Open the PDF for Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders

Jooeun Bae, Robert Smith, John Daley, Naoya Mimura, Yu-Tzu Tai, Kenneth C. Anderson, Nikhil C. Munshi
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4850–4860.
https://doi.org/10.1158/1078-0432.CCR-11-2776
Published: 30 August 2012
View article titled, Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders
Open the PDF for Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders in another window
Journal Articles

Significant Biological Role of Sp1 Transactivation in Multiple Myeloma

Mariateresa Fulciniti, Samir Amin, Puru Nanjappa, Scott Rodig, Rao Prabhala, Cheng Li, Stephane Minvielle, Yu-tzu Tai, Pierfrancesco Tassone, Herve Avet-Loiseau, Teru Hideshima, Kenneth C. Anderson, Nikhil C. Munshi
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (20): 6500–6509.
https://doi.org/10.1158/1078-0432.CCR-11-1036
Published: 14 October 2011
View article titled, Significant Biological Role of Sp1 Transactivation in Multiple Myeloma
Open the PDF for Significant Biological Role of Sp1 Transactivation in Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma

Mariateresa Fulciniti, Teru Hideshima, Claudine Vermot-Desroches, Samantha Pozzi, Puru Nanjappa, Zhenxin Shen, Nipun Patel, Ernest S. Smith, Wei Wang, Rao Prabhala, Yu-tzu Tai, Pierfrancesco Tassone, Kenneth C. Anderson, Nikhil C. Munshi
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (23): 7144–7152.
https://doi.org/10.1158/1078-0432.CCR-09-1483
Published: 30 November 2009
View article titled, A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma
Open the PDF for A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma in another window
Journal Articles

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo

Hiroshi Ikeda, Teru Hideshima, Mariateresa Fulciniti, Robert J. Lutz, Hiroshi Yasui, Yutaka Okawa, Tanyel Kiziltepe, Sonia Vallet, Samantha Pozzi, Loredana Santo, Giulia Perrone, Yu-Tzu Tai, Diana Cirstea, Noopur S. Raje, Christoph Uherek, Benjamin Dälken, Silke Aigner, Frank Osterroth, Nikhil Munshi, Paul Richardson, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (12): 4028–4037.
https://doi.org/10.1158/1078-0432.CCR-08-2867
Published: 15 June 2009
View article titled, The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells <em>In vitro</em> and <em>In vivo</em>
Open the PDF for The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells <em>In vitro</em> and <em>In vivo</em> in another window
Includes: Supplementary data
Journal Articles

Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of Their Functions via Lenalidomide: A Strategy for Immunotherapy

Weihua Song, Hans J.J. van der Vliet, Yu-Tzu Tai, Rao Prabhala, Ruojie Wang, Klaus Podar, Laurence Catley, Masood A. Shammas, Kenneth C. Anderson, Steven P. Balk, Mark A. Exley, Nikhil C. Munshi
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 6955–6962.
https://doi.org/10.1158/1078-0432.CCR-07-5290
Published: 03 November 2008
View article titled, Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of Their Functions via Lenalidomide: A Strategy for Immunotherapy
Open the PDF for Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of Their Functions via Lenalidomide: A Strategy for Immunotherapy in another window
Journal Articles

Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw

Noopur Raje, Sook-Bin Woo, Karen Hande, Jeffrey T. Yap, Paul G. Richardson, Sonia Vallet, Nathaniel Treister, Teru Hideshima, Niall Sheehy, Shweta Chhetri, Brendan Connell, Wanling Xie, Yu-Tzu Tai, Agnieszka Szot-Barnes, Mei Tian, Robert L. Schlossman, Edie Weller, Nikhil C. Munshi, Annick D. Van Den Abbeele, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (8): 2387–2395.
https://doi.org/10.1158/1078-0432.CCR-07-1430
Published: 15 April 2008
View article titled, Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw
Open the PDF for Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw in another window
Journal Articles

Characterization of Signaling Cascades Triggered by Human Interleukin-6 versus Kaposi’s Sarcoma-associated Herpes Virus-encoded Viral Interleukin 6

Teru Hideshima, Dharminder Chauhan, Gerrard Teoh, Noopur Raje, Steven P. Treon, Yu-Tzu Tai, Yoshihito Shima, Kenneth C. Anderson
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (3): 1180–1189.
Published: 01 March 2000
View article titled, Characterization of Signaling Cascades Triggered by Human Interleukin-6 <em>versus</em> Kaposi’s Sarcoma-associated Herpes Virus-encoded Viral Interleukin 6
Open the PDF for Characterization of Signaling Cascades Triggered by Human Interleukin-6 <em>versus</em> Kaposi’s Sarcoma-associated Herpes Virus-encoded Viral Interleukin 6 in another window